BPC 157 / TB500

This blend combines two well-researched synthetic peptides with complementary healing and regenerative properties. BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide studied for its potential roles in tissue repair, angiogenesis, and inflammation regulation. TB-500 (Synthetic Thymosin Beta-4) is a 43-amino acid peptide derived from the naturally occurring Tβ4 peptide of the thymus, studied for its potential in wound healing, cellular motility, and tissue regeneration. As both peptides appear to share overlapping pharmacological potential, their combination may amplify and accelerate the individual effects of each compound.

Chemical Makeup

BPC-157: C62H98N16O22 | 1419.5 g/mol | Also known as: Body Protection Compound-157

TB-500: C212H350N56O78S | 4963 g/mol | Also known as: Thymosin Beta-4

Research Highlights

• Tissue Repair — A 1999 murine wound study found TB-500 produced a 41% increase in re-epithelialization at day 4 and at least 11% greater wound contraction by day 7. A separate BPC-157 study found significantly higher collagen formation and blood vessel development in wounded models vs. placebo.
• Ligaments — Following MCL transection in murine models, TB-500 appeared to promote evenly spaced collagen formation and improved mechanical properties in regenerating tissue. BPC-157 research suggests it may enhance tendon fibroblast migration, F-actin formation, and resilience against oxidative stress via the FAK-paxillin pathway.
• Muscle Repair — In murine models with corticosteroid-induced muscle damage, BPC-157 appeared to produce complete restoration of gastrocnemius muscle function within 14 days vs. no apparent recovery in the placebo group. TB-500 research suggests potential cardiac muscle regeneration benefits, including enhanced myocardial resilience under low-oxygen conditions and possible activation of ILK and protein kinase B pathways.
• Pressure Ulcers — A randomized double-blind trial in 72 subjects with pressure ulcers found TB-500 exposure over 84 days produced observable signs of wound healing across multiple dose groups.

Note: No clinical studies have yet evaluated BPC-157 and TB-500 in direct combination; the above reflects independent research on each peptide.

Available for research and laboratory purposes only.